These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25522335)

  • 1. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers.
    Locati LD; Perrone F; Cortelazzi B; Lo Vullo S; Bossi P; Dagrada G; Quattrone P; Bergamini C; Potepan P; Civelli E; Fallai C; Pilotti S; Licitra L
    Head Neck; 2016 May; 38(5):724-31. PubMed ID: 25522335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.
    Locati LD; Perrone F; Cortelazzi B; Imbimbo M; Bossi P; Potepan P; Civelli E; Rinaldi G; Quattrone P; Licitra L; Pilotti S
    Cancer Biol Ther; 2014 Jun; 15(6):678-82. PubMed ID: 24618694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy.
    Yamamoto N; Minami S; Fujii M
    Am J Otolaryngol; 2014; 35(6):731-5. PubMed ID: 25087467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy.
    Soper MS; Iganej S; Thompson LD
    Head Neck; 2014 Jan; 36(1):E4-7. PubMed ID: 23720164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma.
    Fushimi C; Tada Y; Takahashi H; Nagao T; Ojiri H; Masubuchi T; Matsuki T; Miura K; Kawakita D; Hirai H; Hoshino E; Kamata S; Saotome T
    Ann Oncol; 2018 Apr; 29(4):979-984. PubMed ID: 29211833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options.
    Jaspers HC; Verbist BM; Schoffelen R; Mattijssen V; Slootweg PJ; van der Graaf WT; van Herpen CM
    J Clin Oncol; 2011 Jun; 29(16):e473-6. PubMed ID: 21422415
    [No Abstract]   [Full Text] [Related]  

  • 7. A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol.
    Weijers JAM; Verhaegh GW; Lassche G; van Engen-van Grunsven ACH; Driessen CML; van Erp NP; Jonker MA; Schalken JA; van Herpen CML
    BMC Cancer; 2024 Sep; 24(1):1174. PubMed ID: 39304797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report.
    Sheth H; Kumar P; Shreenivas A; Sambath J; Pragya R; Madre C; Athikari N; Khandare H; Peshattiwar V; Datar R; Limaye S
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34036229
    [No Abstract]   [Full Text] [Related]  

  • 9. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.
    Boon E; van Boxtel W; Buter J; Baatenburg de Jong RJ; van Es RJJ; Bel M; Fiets E; Oosting SF; Slingerland M; Hoeben A; Tesselaar MET; Jonker MA; Flucke UE; ; van der Graaf WTA; van Herpen CML
    Head Neck; 2018 Mar; 40(3):605-613. PubMed ID: 29272069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland.
    Locati LD; Quattrone P; Bossi P; Marchianò AV; Cantù G; Licitra L
    Ann Oncol; 2003 Aug; 14(8):1327-8. PubMed ID: 12881399
    [No Abstract]   [Full Text] [Related]  

  • 11. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined androgen blockade for salivary gland carcinoma.
    Gourd E
    Lancet Oncol; 2018 Jan; 19(1):e17. PubMed ID: 29233558
    [No Abstract]   [Full Text] [Related]  

  • 13. Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer.
    Sekino Y; Han X; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Takeshima Y; Yasui W; Matsubara A
    Urol Oncol; 2020 Oct; 38(10):795.e1-795.e8. PubMed ID: 32430253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature.
    Arce-Salinas C; Riesco-Martinez MC; Hanna W; Bedard P; Warner E
    J Clin Oncol; 2016 Feb; 34(4):e21-4. PubMed ID: 24888812
    [No Abstract]   [Full Text] [Related]  

  • 16. High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy.
    Haller AC; Tan W; Payne-Ondracek R; Underwood W; Tian L; Morrison C; Li F
    Prostate; 2014 May; 74(5):509-19. PubMed ID: 24375440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
    van Boxtel W; Verhaegh GW; van Engen-van Grunsven IA; van Strijp D; Kroeze LI; Ligtenberg MJ; van Zon HB; Hendriksen Y; Keizer D; van de Stolpe A; Schalken JA; van Herpen CM
    Int J Cancer; 2020 Jun; 146(11):3196-3206. PubMed ID: 31745978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy.
    Ham WS; Cho NH; Kim WT; Ju HJ; Lee JS; Choi YD
    J Urol; 2009 Oct; 182(4):1378-84. PubMed ID: 19683286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.
    van Boxtel W; Locati LD; van Engen-van Grunsven ACH; Bergamini C; Jonker MA; Fiets E; Cavalieri S; Tooten S; Bos E; Quattrone P; Verhaegh GW; Schalken JA; Licitra L; van Herpen CML;
    Eur J Cancer; 2019 Mar; 110():62-70. PubMed ID: 30771738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study.
    Locati LD; Bossi P; Perrone F; Potepan P; Crippa F; Mariani L; Casieri P; Orsenigo M; Losa M; Bergamini C; Liberatoscioli C; Quattrone P; Calderone RG; Rinaldi G; Pilotti S; Licitra L
    Oral Oncol; 2009 Jul; 45(7):574-8. PubMed ID: 18804410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.